{"id":432672,"date":"2021-02-10T07:03:40","date_gmt":"2021-02-10T12:03:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=432672"},"modified":"2021-02-10T07:03:40","modified_gmt":"2021-02-10T12:03:40","slug":"md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/","title":{"rendered":"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n

\n HOUSTON<\/span> and SAN DIEGO<\/span>, Feb. 10, 2021<\/span> \/PRNewswire\/ — The University of Texas<\/span> MD Anderson Cancer Center<\/a>\u00a0and\u00a0Mirati Therapeutics, Inc.<\/a>\u00a0(NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two\u00a0investigational small molecule, potent and selective KRAS inhibitors \u2013 adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents \u2013 which target two of the most frequent KRAS mutations in cancer. <\/p>\n

The collaboration will combine\u00a0MD Anderson’s\u00a0clinical trial infrastructure and expertise with Mirati’s differentiated targeted oncology pipeline. Under the terms of the agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, including non-small cell lung, pancreatic, colorectal, and gynecological cancers over the five-year period of the collaboration. <\/p>\n

“This agreement embodies our commitment to further advancing our innovative KRAS programs and complementing our development efforts through strategic collaborations with those who share our vision for breakthrough science,” said Joseph Leveque<\/span>, M.D., Executive Vice President and Chief Medical Officer, Mirati Therapeutics. “We look forward to working with MD Anderson to strengthen our scientific and clinical understanding of KRAS compounds in multiple tumor types with the goal of speeding delivery of new cancer treatments to patients.”\u00a0 <\/p>\n

The collaborative studies\u00a0will be overseen by a joint steering committee. Mirati will provide funding, study materials and other ongoing support throughout the term of the collaboration. \u00a0\u00a0<\/p>\n

“Effective targeted therapies against mutant KRAS could address a major unmet need for many patients,” said Christopher Flowers<\/span>, M.D.<\/a>, ad interim <\/i>division head of Cancer Medicine<\/a> at MD\u00a0Anderson. “Our collaboration with Mirati represents an important opportunity to work toward advancing new treatment options for patients using novel KRAS inhibitors that target two of the most frequent KRAS mutations in common cancers.”<\/p>\n

\n About MD Anderson<\/b>\n <\/p>\n

\n The University of Texas<\/span> MD Anderson Cancer Center<\/a>\u00a0in Houston<\/span> ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990 and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672). <\/p>\n

\n About Mirati Therapeutics<\/b>\u00a0<\/p>\n

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of cancer patients and their loved ones.\u00a0The\u00a0company\u00a0is\u00a0relentlessly focused on\u00a0bringing forward therapies that address\u00a0areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.\u00a0 Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs:\u00a0adagrasib\u00a0(MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and\u00a0sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies.\u00a0 Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer.\u00a0<\/p>\n

For more information about Mirati Therapeutics, visit us at\u00a0Mirati.com<\/a>\u00a0or follow us on\u00a0LinkedIn<\/a>.\u202f\u00a0\u00a0<\/p>\n

\n Forward Looking Statements<\/b>\n <\/p>\n

This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”).\u00a0Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation adagrasib (MRTX849), sitravatinib and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. <\/p>\n

Mirati’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati’s programs are described in additional detail in Mirati’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the “SEC”) available at the SEC’s Internet site (www.sec.gov<\/a>).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.<\/p>\n

\n
\n MD Anderson Media Specialist Contact <\/u>
\n <\/b>\n <\/p>\n

\n Clayton R. Boldt<\/span>, Ph.D.
1-713-792-9518
crboldt@mdanderson.org<\/a><\/p>\n

\n
\n Mirati Contacts <\/u>
\n <\/b>\n <\/p>\n

\n Investor Relations <\/b>
\n
\n Temre Johnson<\/span>
\n
(858) 332-3562
ir@mirati.com<\/a><\/p>\n

\n Media Relations <\/b>
\n
\n Priyanka Shah<\/span>
\n
(908) 447-6134
media@mirati.com<\/a><\/p>\n

\u00a0<\/p>\n

\n

\n
\n \"Logo
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

\n

\n
\n \"\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors-301225517.html<\/a><\/p>\n

SOURCE Mirati Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire HOUSTON and SAN DIEGO, Feb. 10, 2021 \/PRNewswire\/ — The University of Texas MD Anderson Cancer Center\u00a0and\u00a0Mirati Therapeutics, Inc.\u00a0(NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two\u00a0investigational small molecule, potent and selective KRAS inhibitors \u2013 adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents \u2013 which target two of the most frequent KRAS mutations in cancer. The collaboration will combine\u00a0MD Anderson’s\u00a0clinical trial infrastructure and expertise with Mirati’s differentiated targeted oncology pipeline. Under the terms of the agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, … <\/p>\n

Continue reading “MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-432672","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire HOUSTON and SAN DIEGO, Feb. 10, 2021 \/PRNewswire\/ — The University of Texas MD Anderson Cancer Center\u00a0and\u00a0Mirati Therapeutics, Inc.\u00a0(NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two\u00a0investigational small molecule, potent and selective KRAS inhibitors \u2013 adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents \u2013 which target two of the most frequent KRAS mutations in cancer. The collaboration will combine\u00a0MD Anderson’s\u00a0clinical trial infrastructure and expertise with Mirati’s differentiated targeted oncology pipeline. Under the terms of the agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, … Continue reading "MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-10T12:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/341355\/Mirati_Therapeutics_Inc___Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors\",\"datePublished\":\"2021-02-10T12:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/\"},\"wordCount\":938,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/341355\\\/Mirati_Therapeutics_Inc___Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/\",\"name\":\"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/341355\\\/Mirati_Therapeutics_Inc___Logo.jpg\",\"datePublished\":\"2021-02-10T12:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/341355\\\/Mirati_Therapeutics_Inc___Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/341355\\\/Mirati_Therapeutics_Inc___Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors - Market Newsdesk","og_description":"PR Newswire HOUSTON and SAN DIEGO, Feb. 10, 2021 \/PRNewswire\/ — The University of Texas MD Anderson Cancer Center\u00a0and\u00a0Mirati Therapeutics, Inc.\u00a0(NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two\u00a0investigational small molecule, potent and selective KRAS inhibitors \u2013 adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents \u2013 which target two of the most frequent KRAS mutations in cancer. The collaboration will combine\u00a0MD Anderson’s\u00a0clinical trial infrastructure and expertise with Mirati’s differentiated targeted oncology pipeline. Under the terms of the agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, … Continue reading \"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-10T12:03:40+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/341355\/Mirati_Therapeutics_Inc___Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors","datePublished":"2021-02-10T12:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/"},"wordCount":938,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/341355\/Mirati_Therapeutics_Inc___Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/","name":"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/341355\/Mirati_Therapeutics_Inc___Logo.jpg","datePublished":"2021-02-10T12:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/341355\/Mirati_Therapeutics_Inc___Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/341355\/Mirati_Therapeutics_Inc___Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/md-anderson-and-mirati-therapeutics-announce-kras-strategic-research-and-development-collaboration-in-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=432672"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432672\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=432672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=432672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=432672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}